key: cord-0890839-z6qpivc3
authors: Bhatt, Pinki J; Shiau, Stephanie; Brunetti, Luigi; Xie, Yingda; Solanki, Kinjal; Khalid, Shaza; Mohayya, Sana; Au, Pak Ho; Pham, Christopher; Uprety, Priyanka; Nahass, Ronald; Narayanan, Navaneeth
title: Risk Factors and Outcomes of Hospitalized Patients with Severe COVID-19 and Secondary Bloodstream Infections: A Multicenter, Case-Control Study
date: 2020-11-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1748
sha: ac0b766a259c3388409c7fed6b5aed36affb93ce
doc_id: 890839
cord_uid: z6qpivc3

BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic. Clinical characteristics regarding secondary infections in patients with COVID-19 have been reported but detailed microbiology, risk factors and outcomes of secondary bloodstream infections (sBSI) in patients with severe COVID-19 have not been well described. METHODS: We performed a multicenter, case-control study including all hospitalized patients diagnosed with severe COVID-19 and blood cultures drawn from March 1, 2020 to May 7, 2020 at three academic medical centers in New Jersey, USA. Data collection included demographics, clinical and microbiologic variables, and patient outcomes. Risk factors and outcomes were compared between cases (sBSI) and controls (no sBSI). RESULTS: A total of 375 hospitalized patients were included. There were 128 sBSIs during the hospitalization. For the first set of positive blood cultures, 117 (91.4%) were bacterial and 7 (5.5%) were fungal. Those with sBSI were more likely to have altered mental status, lower mean percent oxygen saturation on room air, have septic shock and be admitted to the intensive care unit compared to the controls. In-hospital mortality was higher in those with a sBSI versus controls (53.1% vs 32.8%, p=0.0001). CONCLUSIONS: We observed hospitalized adult patients with severe COVID-19 and sBSI had a more severe initial presentation, prolonged hospital course, and worse clinical outcomes. To maintain antimicrobial stewardship principles, further prospective studies are necessary to better characterize risk factors and prediction modeling to better understand when to suspect and empirically treat for sBSI in severe COVID-19.

M a n u s c r i p t 5

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiology of coronavirus disease 2019 was first identified in Wuhan, China in December 2019. 1 COVID-19 has since become a global pandemic affecting over 21 million lives resulting in over 776,000 deaths as of August 17, 2020. 2 COVID-19 has a wide spectrum of manifestations that contribute to increased morbidity and mortality. 3, 4 Complications range from mild symptoms to hypoxic respiratory failure, acute respiratory distress syndrome, thromboembolic disease, cytokine release syndrome (CRS), multiorgan failure, and in some, secondary infections. 5, 6 Secondary bloodstream infections (sBSI) are well-described in patients with influenza or other viral respiratory illnesses, which occur due to alteration in the epithelial surfaces and immune response resulting in severe inflammation and acquisition of secondary infections. 5, 6 A systematic review in 2018 revealed that one in four patients with Influenza A (H1N1)pmd09 infection had a secondary bacterial infection which led to serious adverse outcomes including intensive care unit (ICU) admission or death. 7 Severe COVID-19 is associated with immune dysregulation which can predispose patients to concurrent bacterial or fungal infections. There are limited data regarding secondary infections in patients with severe COVID-19. 3, 8, 9 Zhang et al. described patients with severe COVID-19 suffered a higher rate of secondary infections compared to patients with non-severe COVID-19. 10 Another study of COVID-19 patients revealed that 50% of non-survivors had a secondary bacterial infection 4 ;

however it did not specify the organism or predisposing risk factors associated with the infection.

Thus, there is a gap in the literature regarding secondary infections, specifically sBSIs, in hospitalized A c c e p t e d M a n u s c r i p t 6 patients with severe COVID- 19 . In this study, we aim to describe epidemiology, risk factors, clinical features, microbiology, and outcomes of patients with severe COVID-19 and sBSI.

This is a multicenter, case-control study of bacterial and fungal sBSI in hospitalized patients diagnosed with severe COVID-19 from March 1, 2020 to May 7, 2020. All patients were followed through June 3, 2020. Eligible patients included those with confirmed COVID-19 by a positive SARS- 

Descriptive statistics were used to describe the sample of COVID-19 patients, including mean and standard deviation, median and interquartile range, range for continuous variables and proportions for categorical variables. Risk factors and outcomes were compared between cases (sBSI) and controls (no sBSI). Group comparisons were performed using two sample ttests for normally-distributed continuous variables and Mann-Whitney U-tests for nonnormally-distributed continuous variables. Differences in proportions were compared using a Chi-square test or Fisher's exact test. Logistic regression was used to calculate odds ratios and 95% confidence intervals for associations between risk factors and sBSI adjusted for age, sex, and race. All tests of significance are two-tailed. Alpha was set at 0.05. Propensity score A c c e p t e d M a n u s c r i p t 8 matching was performed using the radius method in SAS. 12, 13 Analyses were performed using SAS version 9.4 (Cary, North Carolina, USA).

A total of 1,735 adult patients were identified at 3 centers in New Jersey (34.7% RWJUH, 24.0% RWJ-S, and 41.3% UH) with COVID-19 between March 1, 2020 and May 7, 2020.

After applying exclusion criteria, 375 patients were included (Figure 1) . Participant characteristics are shown in Table 1 were positive for Candida albicans/Candida tropicalis (4, 80%) and Candida parapsilosis (1, 20%) . None of the positive T2 Candida PCR were considered to be a contaminant. The most common presumed source was unknown/not reported followed by abdomen. The overall median time of sBSI in our cohort was 3 days (IQR 2-6). Among all patients with sBSI, 50.8% were considered nosocomial acquisition as defined by positive blood cultures >48 hours from time of admission.

Cases and controls were compared to evaluate for risk factors for sBSI ( Table 2) . Patients with sBSI were less likely to have cough (45.3% vs 65.2%, p=0.0002) and fever (54.7% vs 66.8%, p=0.02) as a presenting symptom compared to those without sBSI, however AMS (23.4% vs 11.7%, p=0.003) was more common in those with sBSI. The number of patients with diarrhea or abdominal pain as a presenting symptom was not different between groups.

The mean percent oxygen saturation on room air upon initial presentation was lower in those with sBSI compared to controls (82.5% vs 86.1%). More patients with sBSI were intubated compared to the controls (23.8% vs 8.1%; p<0.0001) on the day of positive COVID-19 test.

Mean baseline white blood cell count (WBC) (10.9 vs 8.6, p<0.001) and creatinine (2.23 vs 1.49, p=0.001) was higher in the sBSI than the controls. Those with sBSI were more likely to have a central line (78.1% vs 32%; p<0.0001) with a mean duration of 7.1 days prior onset of BSI. Invasive procedures including endotracheal intubation (65.6% vs 29.6%, p<0.0001) and CVVH/hemodialysis (35.9% vs 9.3%, p<0.0001) were common in those with sBSI compared to controls. All findings remained consistent in multivariable logistic regression models adjusting for age, sex, and race.

A c c e p t e d M a n u s c r i p t 10 Data for treatment and outcomes are shown in Table 3 . Septic shock requiring vasopressors (55.5% vs 14.2%, p<0.001), use of antimicrobial therapy (99.2% vs 70.5%, p<0.001) and use of systemic glucocorticoids (32% vs 17.8%, p=0.002) was more common in those with sBSI.

The most common empirical antimicrobials were ceftriaxone, azithromycin, and piperacillintazobactam. Median length of hospital stay was significantly longer in the sBSI group (18.5 days vs 7 days, p<0.001). Patients with sBSI were also more likely to require ICU admission (71.1% vs 35.6%, p<0.001) with a longer median length of ICU stay (17 days vs 6.5 days, p<0.001). More patients with sBSI died in-hospital compared to those without (53.1% vs 32.8%, p=0.0001). As of June 3, 2020, more patients without sBSI were alive and discharged from the hospital (98.8% vs 63.3%, p<0.0001) whereas those with sBSI were still hospitalized (36.7% vs 1.2%, p<0.0001). All findings, including mortality, remained consistent in multivariable logistic regression models adjusting for age, sex, and race as well as a propensity score matched analysis (Supplementary Table 2) . Additionally, among patients with sBSI, proportion of death did not vary by nosocomial acquisition status.

To our knowledge, this is the first study to assess the microbiology, risk factors and outcomes in hospitalized patients with severe COVID-19 with sBSIs. We observed that patients with more advanced types of supplemental oxygen on admission was associated with higher odds of sBSI.

Interestingly, there were significantly less patients with sBSI presenting with cough and fever but rather with AMS, higher WBC, higher serum creatinine. Additionally, in our secondary descriptive analysis, we observed patients with sBSIs were more likely to require intubation, renal replacement therapy, and had worse clinical outcomes including septic shock requiring vasopressors, admission A c c e p t e d M a n u s c r i p t 11 to ICU, longer hospital length of stay, longer length of ICU stay, and greater in-hospital mortality. In summary, patients with sBSI were significantly more ill upon presentation and had poorer outcomes.

The sBSIs observed in COVID-19 patients may have contributed to the more severe presentation and clinical course and/or reflect other underlying physiological and immunological complications of COVID-19. Alternatively, a complicated hospital course may have contributed to acquiring more risk factors for developing sBSI.

In our cohort, the majority of BSIs had an unknown source. However, CLABSI was found to be the most common presumed source of sBSI. Prior studies report bacterial pneumonia as the primary source of bacteremia in those with influenza or other coronaviruses. 14 This has infection control implications as the presence of airborne/contact precautions and fear of prolonged patient contact and aerosolization could be a barrier to good catheter hygiene and maintenance, increasing the risk of CLABSI. Alternatively, patients with sBSI were more likely to require longer hospitalization or ICUstay thus predisposing them to a prolonged indwelling line and developing CLABSI. As previously reported, 15 we also found that the most common cause of bacteremia was due to Staphylococcus aureus, Enterococcus faecalis and Escherichia coli.

We observed numerous cases of fungemia caused by Candida species which is in contrast to previous reports. 14,16 One notable finding was a positive blood culture for Cryptococcus neoformans. A recent study assessing blood culture utilization in New York City observed a significant proportion of contaminant blood cultures. 15 In our study, we noted a large number of blood cultures deemed to be a contaminant before or after the first positive blood culture with true pathogen. At the time of this study, New Jersey was experiencing a surge in cases along with New York City. This undoubtedly caused a strain on the health care system causing a lack of PPE and affecting how some of the blood cultures may have been drawn. Additionally, the presence of airborne/contact isolation likely affected the quality of blood culture draws at the time.

Presenting symptoms such as fever, cough and dyspnea have been widely reported in severe COVID-19. 4,10,21 However, our findings indicated that AMS was a more common presenting symptom in patients with sBSI while fever and cough were less common. Additionally, the higher prevalence of leukocytosis and acute kidney injury in the sBSI cohort represent classical markers of immune response to systemic infection and organ dysfunction secondary to impending onset of septic shock as noted in prior epidemiological studies of COVID-19. 4 Lastly, we observed that patients with sBSI present to the hospital in more severe respiratory distress as noted by lower oxygen saturation and need for advanced oxygen supplementation. These presenting symptoms may reflect a superimposed effect of bacterial or fungal sepsis with severe COVID-19 or a marker of critical illness due to COVID-19 itself. Similar clinical manifestations of respiratory failure and sepsis have been noted in patients with secondary infections and influenza, 22,23 but there are limited data describing this level of critical illness in other viral infections. We hypothesized that the presence of abdominal pain or diarrhea on admission may be a risk factor for developing sBSI due to an enteric organism; M a n u s c r i p t 13 however, this was not observed. Diabetes mellitus plays a significant role in the severity of COVID-19 24-27 however our study did not find it to be a risk factor for sBSI. Increased morbidity and mortality associated with secondary bacterial infections has been welldescribed for prior influenza pandemics but there are limited data for SARS-CoV-2. 29 In our study, clinical outcomes were significantly worse for patients with sBSI as noted by higher percentage of septic shock, admission to ICU, longer length of hospital and ICU stay and higher in-hospital mortality. The significant differences remained consistent with both multivariable regression and propensity score matched analyses. While previous studies 16, 30 have described co-infections in COVID-19 patients, number of cases lack detailed case descriptions. Across three academic medical A c c e p t e d M a n u s c r i p t 14 centers in New Jersey, we were able to examine 128 patients with sBSI. The in-hospital mortality rate was over 50% for these patients. We emphasize caution in conclusions related to clinical outcomes such as mortality as the primary intent of our case-control study was to examine risk factors associated with sBSI in COVID-19 patients and was not a cohort study intended to examine predictors of mortality.

Our study had some limitations. First, the retrospective, observational design limits understanding of clinical decisions. Many patients had missing variables depending on their clinical course or physician's discretion at time of care. We did not collect data such as cultures of other types of secondary infections or cause of mortality as this information was incomplete in the EMR. We focused on sBSI given the higher level of diagnostic certainty for retrospective investigation. Second, lack of standardized care given the novelty of the virus resulted in heterogenous management within and among hospitals. This may have also contributed to poor clinical outcomes which we are unable to reasonably distinguish. Third, although our sample size is relatively large for this complication, our study does not use a nationally representative sample. Therefore, results must be carefully interpreted before generalizing to differing populations or geographical regions. Fourth, misclassification between contaminant versus pathogens was possible as we relied on the documentation of the clinical team's interpretation at the time of data collection. Lastly, the source of sBSI was primarily based on correlation to other positive body site cultures with the same organism and the clinical team's assessment. It is difficult to discern the true source for a retrospective study.

Our study has several strengths. First, to our best knowledge, this is the first multicenter study to examine detailed microbiology, risk factors and outcomes in hospitalized patients with severe 

A Novel Coronavirus from Patients with Pneumonia in China

COVID-19 Dashboard by the

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Mechanisms of Severe Mortality-Associated Bacterial Co-infections Following Influenza Virus Infection

Secondary bacterial infections in influenza virus infection pathogenesis

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09

Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

CDC/NHSN surveillance definition of health careassociated infection and criteria for specific types of infections in the acute care setting

Too much ado about propensity score models? Comparing methods of propensity score matching

A general SAS macro to implement optimal N: 1 propensity score matching within a maximum radius

Co-infections in people with COVID-19: a systematic review and meta-analysis

Bacteremia and Blood Culture Utilization During COVID-19 Surge in New York City

Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient

COVID-19 associated pulmonary aspergillosis

COVID-19-associated Pulmonary Aspergillosis

A c c e p t e d M a n u s c r i p t 17 M a n u s c r i p t 20 A c c e p t e d M a n u s c r i p t 22